At Genprex, our mission is to advance novel gene therapies for patients afflicted with cancer and diabetes.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. We work with world-class institutions and collaborators to develop drug candidates to further our pipeline of gene therapies in order to provide novel treatment approaches.
Our Story
Genprex was co-founded in 2009 by David Nance and Rodney Varner out of Austin, Texas. After the financial crisis of 2008, Nance and Varner acquired Genprex’s current Reqorsa® Immunogene Therapy technology from a former biotech company. The two co-founders found the technology to be promising based on preclinical and clinical data from researchers, including oncologist Dr. Jack Roth at MD Anderson Cancer Center.
The co-founders had a passion for finding a new treatment option for patients with cancer, and their devotion continues to be the backbone of Genprex’s DNA today. The Company’s original Chief Executive Officer, David Nance, passed away of cancer in 2012. Since that time, Rodney Varner served as the Company’s CEO until he passed away in 2024 from complications of cancer.
Their legacy continues to fuel Genprex’s mission to find new treatment options for those suffering from debilitating diseases, particularly cancer and diabetes.